These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

133 related articles for article (PubMed ID: 33271136)

  • 21. Processing Impact on Monoclonal Antibody Drug Products: Protein Subvisible Particulate Formation Induced by Grinding Stress.
    Gikanga B; Eisner DR; Ovadia R; Day ES; Stauch OB; Maa YF
    PDA J Pharm Sci Technol; 2017; 71(3):172-188. PubMed ID: 27789805
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Evaluation of aggregate and silicone-oil counts in pre-filled siliconized syringes: An orthogonal study characterising the entire subvisible size range.
    Shah M; Rattray Z; Day K; Uddin S; Curtis R; van der Walle CF; Pluen A
    Int J Pharm; 2017 Mar; 519(1-2):58-66. PubMed ID: 28089934
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Evaluating a Modified High Purity Polysorbate 20 Designed to Reduce the Risk of Free Fatty Acid Particle Formation.
    Doshi N; Ritchie K; Shobha T; Giddings J; Gregoritza K; Taing R; Rumbelow S; Chu J; Tomlinson A; Kannan A; Saggu M; Cai SK; Nicoulin V; Liu W; Russell S; Luis L; Yadav S
    Pharm Res; 2021 Sep; 38(9):1563-1583. PubMed ID: 34495486
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Mechanistic Investigation on Grinding-Induced Subvisible Particle Formation during Mixing and Filling of Monoclonal Antibody Formulations.
    Gikanga B; Hui A; Maa YF
    PDA J Pharm Sci Technol; 2018; 72(2):117-133. PubMed ID: 29030532
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Controlled polysorbate 20 hydrolysis - A new approach to assess the impact of polysorbate 20 degradation on biopharmaceutical product quality in shortened time.
    Graf T; Abstiens K; Wedekind F; Elger C; Haindl M; Wurth C; Leiss M
    Eur J Pharm Biopharm; 2020 Jul; 152():318-326. PubMed ID: 32445968
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Human Serum Albumin Mitigates Formation of Fatty Acid Particles in Polysorbate-Containing Solutions.
    Kim DM; Stansberry-Perkins K; Marlow MS; Pyles EA
    J Pharm Sci; 2022 Nov; 111(11):3185-3188. PubMed ID: 35977591
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Impact of Polysorbate 80 Grade on the Interfacial Properties and Interfacial Stress Induced Subvisible Particle Formation in Monoclonal Antibodies.
    Vaclaw C; Merritt K; Pringle V; Whitaker N; Gokhale M; Carvalho T; Pan D; Liu Z; Bindra D; Khossravi M; Bolgar M; Volkin DB; Ogunyankin MO; Dhar P
    J Pharm Sci; 2021 Feb; 110(2):746-759. PubMed ID: 32987092
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of Subvisible Particles in Biotherapeutic Prefilled Syringes: The Role of Polysorbate and Protein on the Formation of Silicone Oil and Protein Subvisible Particles After Drop Shock.
    Jiao N; Barnett GV; Christian TR; Narhi LO; Joh NH; Joubert MK; Cao S
    J Pharm Sci; 2020 Jan; 109(1):640-645. PubMed ID: 31689431
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Monitoring polysorbate hydrolysis in biopharmaceuticals using a QC-ready free fatty acid quantification method.
    Honemann MN; Wendler J; Graf T; Bathke A; Bell CH
    J Chromatogr B Analyt Technol Biomed Life Sci; 2019 May; 1116():1-8. PubMed ID: 30951966
    [TBL] [Abstract][Full Text] [Related]  

  • 30. An Approach to Mitigate Particle Formation on the Dilution of a Monoclonal Antibody Drug Product in an IV Administration Fluid.
    Zheng S; Adams M; Mantri RV
    J Pharm Sci; 2016 Mar; 105(3):1349-50. PubMed ID: 26886343
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Evaluation of Super Refined™ Polysorbate 20 With Respect to Polysorbate Degradation, Particle Formation and Protein Stability.
    Doshi N; Fish R; Padilla K; Yadav S
    J Pharm Sci; 2020 Oct; 109(10):2986-2995. PubMed ID: 32679214
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Residual Host Cell Protein Promotes Polysorbate 20 Degradation in a Sulfatase Drug Product Leading to Free Fatty Acid Particles.
    Dixit N; Salamat-Miller N; Salinas PA; Taylor KD; Basu SK
    J Pharm Sci; 2016 May; 105(5):1657-1666. PubMed ID: 27032893
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Novel markers to track oxidative polysorbate degradation in pharmaceutical formulations.
    Dahotre S; Tomlinson A; Lin B; Yadav S
    J Pharm Biomed Anal; 2018 Aug; 157():201-207. PubMed ID: 29803911
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate.
    Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N
    Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Characterization of Proteinaceous Particles in Monoclonal Antibody Drug Products Using Mass Spectrometry.
    Xu X; Hu Q; Liu D; Qiu H; Shameem M; Li N
    J Pharm Sci; 2021 Oct; 110(10):3403-3409. PubMed ID: 34139261
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Compatibility, physical stability, and characterization of an IgG4 monoclonal antibody after dilution into different intravenous administration bags.
    Kumru OS; Liu J; Ji JA; Cheng W; Wang YJ; Wang T; Joshi SB; Middaugh CR; Volkin DB
    J Pharm Sci; 2012 Oct; 101(10):3636-50. PubMed ID: 22733600
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Hydrolysis of Polysorbate 20 and 80 by a Range of Carboxylester Hydrolases.
    McShan AC; Kei P; Ji JA; Kim DC; Wang YJ
    PDA J Pharm Sci Technol; 2016; 70(4):332-45. PubMed ID: 27020650
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Ester hydrolysis of polysorbate 80 in mAb drug product: evidence in support of the hypothesized risk after the observation of visible particulate in mAb formulations.
    Labrenz SR
    J Pharm Sci; 2014 Aug; 103(8):2268-77. PubMed ID: 24942482
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Degradation of Polysorbate 20 by Sialate O-Acetylesterase in Monoclonal Antibody Formulations.
    Zhang S; Xiao H; Li N
    J Pharm Sci; 2021 Dec; 110(12):3866-3873. PubMed ID: 34487744
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fate of antibody and polysorbate particles in a human serum model.
    Schuster J; Kamuju V; Mathaes R
    Eur J Pharm Biopharm; 2022 Feb; 171():72-79. PubMed ID: 34920132
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.